Triple-Negative Breast Cancer (TNBC) is a highly invasive, under-researched subtype of Breast Cancer. Patients lack receptors for the protein Human Epidermal Growth Factor, and both estrogen and progesterone. This negatively impacts treatment by making all hormone-sensitive treatments unavailable to TNBC patients. Since the effectiveness of various options has remained understudied, the prognosis remains poor. This paper attempts to analyze and compare the effectiveness of various treatment options. Because TNBC is very aggressive, the standard approach is to jump in with harsh surgical procedures, including mastectomies and lumpectomies. This analysis finds that more aggressive treatment may not be necessary to treat all TNBC patients. The addition of immuno and platinum therapies to traditional chemotherapy appears to increase survival to the same extent as that of mastectomies and lumpectomies. It also appears that radiation therapy greatly enhances treatment and may be an option to avoid a full radical mastectomy as the survival rates proved to be higher in patients with radiation therapy in conjunction with lumpectomies. More research is needed; however, aggressive therapies do not need to be the first choice as the other options appear to provide just as high, if not higher survival rates.
Dusowitz, E. (2022). An Analysis on Various Treatment Options for Triple-Negative Breast Cancer. The Science Journal of the Lander College of Arts and Sciences, 15(2), 10-15. Retrieved from https://touroscholar.touro.edu/sjlcas/vol15/iss2/3